Dapagene Tablets 5mg (Dapagliflozin Anhydrous Mixture)
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
MFDS item code 202005361 · Approved 2020.07.23
This product's status changed to Expired on 2025.07.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This drug is used along with dietary and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. It can be used alone or in conjunction with other medications. It is particularly helpful in cases where blood sugar control is difficult, and it can be cautiously applied to patients with cardiovascular diseases or risk factors. For detailed information, please refer to professional clinical trial information. This drug is used to improve blood sugar control in patients with type 2 diabetes.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10 mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received drug therapy for diabetes, when this medicine is administered in combination with metformin, the recommended initial dose is 5 mg once daily or 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary for patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
Under 18 years of age: The efficacy and safety of dapagliflozin have not been established. No relevant data are available.
This drug should not be used in patients who are allergic to the active ingredients or excipients of this drug. It is also not safe to administer to patients with type 1 diabetes or diabetic ketoacidosis. Patients with genetic conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not take this drug as it contains anhydrous lactose. Patients undergoing dialysis should also not use this drug. Caution should be exercised when administering to patients with low fluid volume or poor kidney function. This drug can cause hypotension or worsen kidney function due to reduced intravascular volume; therefore, assessment of fluid status and kidney function must be performed before administration. After administration, symptoms of hypotension and changes in kidney function should be regularly monitored. This drug contains specific dyes, Yellow No. 4 and Yellow No. 5, and should be used cautiously in patients with allergies or a history of hypersensitivity to these components. During the course of taking this drug, genital infections or urinary tract infections may occur, so immediate treatment is necessary if symptoms of infection arise. There may also be symptoms of hypoglycemia, so dosage adjustments may be needed when taken with insulin or sulfonylureas to reduce the risk of hypoglycemia. Dehydration symptoms or dry mouth may occur due to decreased fluid volume, so adequate fluid intake and symptom monitoring are important. In severe cases, drug administration may be temporarily suspended. This drug may increase the risk of diabetic ketoacidosis; therefore, if symptoms of ketoacidosis such as vomiting, abdominal pain, or difficulty breathing occur, immediate medical attention is required. Elderly patients or those with reduced kidney function may be particularly sensitive to side effects of this drug and require careful management and monitoring. It is advisable for pregnant or breastfeeding women to avoid using this drug, and if pregnancy is confirmed, administration should be immediately stopped. There is no specific antidote for overdose, so appropriate treatment and observation are required based on symptoms. This drug does not significantly affect driving or machinery operation, but caution is needed due to the risk of hypoglycemia.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly sealed container to protect it from air and moisture. The storage temperature should be maintained between 1 and 30 degrees Celsius to preserve the drug's efficacy and safety for longer periods.
Yellow, biconvex, round film-coated tablet
28 Tablets/PTP[(7 Tablets/PTP×4, 14 Tablets/PTP×2)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Sinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Albozen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.